Background. Personalized medicine, targeted to a particul ar patient, is getting increased recognition. Genetic testing is successfully applied in oncology, haematology and other fields of medicine. However, clinical application in psychiatry is still awaited. In the spotlight is genetic polymorphism of CYP450 family enzymes that are responsible for a substantial part of psychotropic drugs metabolism. In this ar ti cle we are seeking to evaluate the utility of pharmacogenetic testing of genes that code these enzymes.